Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2259410 | 0.86 | EPHX2 (0.56) | EPHX2GAAHTTSMN1; SMN2LMNA | |
| SCHEMBL2786343 | 0.84 | EPHX2 (0.57) | EPHX2GAAHTTSMN1; SMN2KDM4E | |
| SCHEMBL3475524 | 0.83 | EPHX2 (0.66) | EPHX2GAAHTTSMN1; SMN2KDM4E | |
| SCHEMBL13876177 | 0.82 | EPHX2 (0.61) | EPHX2GAAHTTKDM4EP2RX7 | |
| SCHEMBL2786704 | 0.82 | EPHX2 (0.66) | EPHX2GAAHTTP2RX7 | |
| SCHEMBL2261513 | 0.81 | EPHX2 (0.66) | EPHX2GAAHTTSMN1; SMN2 | |
| SCHEMBL2258231 | 0.80 | EPHX2 (0.80) | EPHX2 | |
| SCHEMBL3473829 | 0.78 | SMN1; SMN2 (0.69) | EPHX2GAAHTTSMN1; SMN2KDM4E | |
| SCHEMBL2787853 | 0.78 | EPHX2 (0.67) | EPHX2GAAHTTSMN1; SMN2P2RX7 | |
| SCHEMBL3475200 | 0.78 | P2RX7 (0.49) | EPHX2GAAHTTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209376-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2209376-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, CYP46A1 | EPHX2 4/4885GAA 487/4885HTT 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.